Insulin delivery company Insulet Corporation (NASDAQ: PODD) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 31.2% year on year to $783.8 million. The company expects next quarter’s revenue to be around $716.9 million, close to analysts’ estimates. Its non-GAAP profit of $1.55 per share was 6% above analysts’ consensus estimates.

Is now the time to buy PODD? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Insulet’s fourth quarter results received a strong positive market response, reflecting both robust top-line growth and margin expansion. Management pointed to record new customer starts across both the U.S. and international markets, driven primarily by Omnipod’s continued adoption among people with type 2 diabetes and notable gains in international geographies. CEO Ashley McEvoy emphasized that Omnipod’s clinical outcomes and ease of use contributed to increasing prescriber confidence, noting, “we achieved record new customer starts across both the U.S. and international in the fourth quarter and for the full year, with the vast majority coming from people transitioning from multiple daily injections.”

Looking ahead, Insulet’s forward guidance is underpinned by expectations for further penetration of automated insulin delivery (AID) systems among both type 1 and type 2 diabetes populations, expansion into new geographies, and ongoing product innovation. Management highlighted upcoming enhancements, including expanded sensor integrations and the launch of Omnipod Discover, a new data platform. CFO Flavia Pease stated that 2026 guidance reflects “continued top-tier market-leading growth,” though year-over-year comparisons will be impacted by the anniversary of major product launches. The company plans to advance its next-generation platforms, including Omnipod 6 and a fully closed-loop system for type 2 diabetes, while maintaining a disciplined approach to investment and margin expansion.

Key Insights from Management’s Remarks

Management attributed quarterly outperformance to record new customer starts, particularly among type 2 diabetes users, and successful international market expansion. Ongoing product innovation and manufacturing scale-up were also highlighted as supporting factors.

• Type 2 diabetes momentum: Insulet saw significant sequential and year-over-year growth in type 2 new customer starts, attributed to updated clinical guidelines, increased primary care engagement, and compelling real-world outcomes for Omnipod 5.
• International expansion success: Strong performance in European markets, as well as rapid adoption following launches in Canada and Australia, fueled international growth. Reimbursement wins and sensor integrations, such as with Dexcom G7 in Germany, supported this trend.
• Product innovation pipeline: The company advanced key programs, including the STRIVE study for Omnipod 6 and the EVOLUTION study for its fully closed-loop system, aiming to address unmet needs in the diabetes community and support broader automated insulin delivery adoption.
• Commercial and prescriber reach: Insulet expanded its U.S. prescriber base by 28% year-over-year and invested in a larger sales force, making Omnipod 5 accessible through approximately 48,000 pharmacies and covered for over 90% of insured lives in the U.S.
• Manufacturing and operational scale: Productivity gains at the Malaysia and Acton facilities contributed to margin expansion, while further automation and global manufacturing investments are expected to support continued growth and cost efficiencies.

Drivers of Future Performance

Insulet’s outlook is supported by expectations for AID system adoption, new product rollouts, and international market expansion, though management highlighted tougher year-over-year comparisons ahead.

• Product enhancement and pipeline: Management plans to release Omnipod algorithm updates, broaden CGM (continuous glucose monitor) compatibility, and launch Omnipod Discover, aiming to improve user experience, adherence, and clinical outcomes. These rollouts are expected to drive further adoption, particularly among primary care providers.
• International and type 2 penetration: Continued expansion into new international markets and deeper inroads with type 2 diabetes patients are seen as key growth drivers. However, management acknowledged that as recent launches annualize, growth rates may moderate compared to prior periods.
• Margin expansion and investment: Insulet expects to achieve operating margin gains through manufacturing productivity, increased automation, and disciplined SG&A spending, even as R&D investments rise to support next-generation products. Management did note that capital expenditures will ramp up to support global manufacturing expansion, which may keep free cash flow flat year-over-year.

Catalysts in Upcoming Quarters

In the coming quarters, we will closely watch (1) the pace of type 2 diabetes customer adoption in both U.S. and international markets, (2) the rollout and uptake of Omnipod Discover and expanded sensor integrations, and (3) margin trends as manufacturing expansion and automation initiatives scale. Progress on clinical programs for next-generation systems and the ability to maintain strong prescriber engagement will also be key indicators of Insulet’s execution.

Insulet currently trades at $259.75, up from $246.34 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

High Quality Stocks for All Market Conditions

The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.